Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants Article Swipe
Related Concepts
Medicine
Palivizumab
Pharmacotherapy
Respiratory system
Virus
Intensive care medicine
Virology
Pediatrics
Internal medicine
Chiara Bini
,
Andrea Marcellusi
,
Daniele Cazzato
,
Barbara Muzii
,
Sabrine Soudani
,
Elena Bozzola
,
Fabio Midulla
,
Eugenio Baraldi
,
Paolo Bonanni
,
Sara Boccalini
,
Luigi Orfeo
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40261-025-01437-8
· OA: W4410057150
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40261-025-01437-8
· OA: W4410057150
A prophylaxis strategy against RSV infection targeting all infants with nirsevimab could represent a cost-effective option for both NHS and societal perspectives, and supports the implementation and the equity of RSV prevention for all infants.
Related Topics
Finding more related topics…